Dirk is Managing Partner and manages the Forbion Growth Opportunities Fund. He joined Forbion in 2018.
Dirk has a key role in the investment team and has experience in general fund management, deal making, portfolio management and exit strategies. Dirk is a physicist by training and previously worked as a Partner at Gilde Healthcare Partners, where he led their Boston office.
Dirk was a Managing Director at INKEF Capital responsible for all healthcare related investment activities. Dirk led a series of investments in Europe and the US, including: Dyne Therapeutics (NASDAQ: DYN), Ascendis Pharma (NASDAQ: ASND), Profibrix (acquired by MEDCO), Lanthio Pharma (acquired by Morphosys), Nightbalance (acquired by Philips) and is currently on the Boards of Dyne Therapeutics (DYN), Synox Therapeutics and NorthSea Therapeutics.
Portfolio
Companies worked on by Dirk Kersten
